Showing 1881-1890 of 5957 results for "".
- RegeneRx and Lee’s Pharm to Accelerate RGN-259 Development in Chinahttps://modernod.com/news/regenerx-and-lees-pharm-to-accelerate-rgn-259-development-in-china/2476417/RegeneRx Biopharmaceuticals and Lee’s Pharmaceutical Holdings, a Hong Kong-based pharmaceutical company, are accelerating development of RGN-259 in China for ophthalmic indications. Lee’s Pharm previously licensed RGN-2
- Johnson & Johnson Vision’s Investigational Antihistamine-Releasing Contact Lens Demonstrates Positive Phase 3 Resultshttps://modernod.com/news/johnson-johnson-visions-investigational-antihistamine-releasing-contact-lens-demonstrates-positive-phase-3-results/2476418/Johnson & Johnson Vision announced that results from two phase 3 clinical studies evaluating the company’s investigational antihistamine-releasing contact lens (etafilcon A with 0.019 mg ketotifen) were published in the journal Cornea. The results demonstrated that patients weari
- ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10https://modernod.com/news/proqr-reaches-agreement-with-the-fda-on-design-of-phase-2-3-pivotal-trial-for-sepofarsen-qr-110-for-lebers-congenital-amaurosis-10/2476214/ProQR Therapeutics announced that it has reached agreement with the FDA on the design of a phase 2/3 pivotal trial (ILLUMINATE) for QR-110, now renamed to sepofarsen, in patients with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290gene. LCA is the lead
- Santen Expands Research and Development Leadership Teamhttps://modernod.com/news/santen-expands-research-and-development-leadership-team/2479666/Santen announced the expansion of its research and development leadership team through the addition of two new executive hires. Reza M. Haque, MD, PhD, has been appointed as Senior Vice President, Global Research and Development Strategy, and Peter Sallstig, MD, MBA
- LEH Pharma Appoints Syneos Health as Global Clinical Development and Commercialization Solutions Providerhttps://modernod.com/news/leh-pharma-appoints-syneos-health-as-global-clinical-development-and-commercialization-solutions-provider/2479769/LEH Pharma, a provider of ocular implants for macular disorders, announced the selection of Syneos Health, a fully integrated biopharmaceutical solutions organization, as its global clinical development and commercialization provider. The primary aim of the strategic relationship is to acc
- Excel-Lens Announces CE Mark Approval for CAPSULaser Selective Laser Capsulotomy (SLC) Devicehttps://modernod.com/news/excel-lens-announces-ce-mark-approval-for-capsulaser-selective-laser-capsulotomy-slc-device/2479872/Excel-Lens announced the CE mark approval of CAPSULaser, a selective laser that creates a capsulotomy during cataract surgery in just over a second. The laser energy is delivered in a continuous manner rather than a pulsed beam which can create tissue bridges. In clinical studies, CAPSULas
- PulseSight Therapeutics Initiates Clinical Plan of PST-611 Transferrin Vectorized Therapy for Dry AMD/GAhttps://modernod.com/news/pulsesight-therapeutics-initiates-clinical-plan-of-pst-611-transferrin-vectorized-therapy-for-dry-amdga/2482615/PulseSight Therapeutics SAS announced it has submitted a clinical trial authorization (CTA) to Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM) for a phase 1 trial (PST-611-CT1) assessing the safety
- J&J Vision Presents Data Validating Improved Surgical Outcomes and Surgeon Satisfaction at ASCRShttps://modernod.com/news/johnson-johnson-vision-presents-data-validating-improved-surgical-outcomes-and-surgeon-satisfaction-across-cataract-and-refractive-portfolio-at-ascrs/2480787/Johnson & Johnson Vision will present and/or support 46 company-sponsored and investigator-led studies evaluating innovations and outcomes across its surgical portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Washington, DC, April 22-26.
- Alcon Announces Scientific Program at ASCRS 2022https://modernod.com/news/alcon-announces-scientific-program-at-ascrs-2022/2480782/Alcon will once again have a significant scientific presence at the American Society of Cataract and Refractive Surgery (ASCRS) 2022 annual meeting, taking place April 22-26 in Washington, DC. Approximately 150 abstracts feature Alcon’s leading ophthalmic products and equipment—with m
- Tarsus Pharmaceuticals Appoints Wendy Yarno to Board of Directorshttps://modernod.com/news/tarsus-pharmaceuticals-appoints-wendy-yarno-to-board-of-directors/2478584/Tarsus Pharmaceuticals announced the appointment of Wendy L. Yarno to its Board of Directors and its audit committee. Ms. Yarno has more than 30 years of experience in the biopharmaceutical industry, as a public company director and product commercialization leader, including 26 years at Merck &a